Prevalence of Anemia among Chronic Myeloid Leukemia Patients Treated with Imatinib: A Evidence-based Meta-analysis-Reference-Cited by-同舟云学术

Prevalence of Anemia among Chronic Myeloid Leukemia Patients Treated with Imatinib: A Evidence-based Meta-analysis

Published:2023-07 Issue:2 Volume:18 Page:148-157
ISSN:2772-4328
Container-title:Current Reviews in Clinical and Experimental Pharmacology
language:en
Short-container-title:CRCEP

Author:

Sharma Manju¹,Singh Avinash Kumar²³,Kumar Anoop⁴,Agrawal Narendra³,Bhurani Dinesh³,Ahmed Rayaz³

Affiliation:

1. Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi-110062, India

2. Department of Pharmaceutical Medicine (Division of Pharmacology), School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi-110062, India

3. Department of Hemato-Oncology & BMT Unit, Rajiv Gandhi Cancer Institute, and Research Centre, Sector - 5, Rohini, Delhi-110085, India

4. Department of Pharmacology & Clinical Research, Delhi Pharmaceutical Sciences and Research University (DPSRU), Mehrauli-Badarpur Road, Puspvihar Sector 3, New Delhi 110017, India

Abstract

Backgrounds: Imatinib is one of the tyrosine kinase inhibitors used for the treatment of chronic myeloid leukemia (CML) patients. The exact association of imatinib with anemia in CML patients is still unclear. Aim: The current study aimed to find the prevalence of anemia in chronic myeloid leukemia patients treated with imatinib. Methods: The relevant articles were searched in PubMed, Google scholar, and Clinical trials registries till 31st July, 2021. The quality of the articles was assessed using the Newcastle-Ottawa Scale. The prevalence rate with 95% CI was calculated using StatsDirect Statistical analysis software V.3. Results: A total of 18 studies containing 3537 patients were found relevant for the analysis. The pooled prevalence of anemia in CML was found to be 34% (95% CI: 23%-46%). However, the heterogeneity among studies was found to be high. Conclusion: The monitoring of hemoglobin levels and identifying the cause of anemia are major concerns for the CML patients treated with Imatinib.

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics

Reference20 articles.

1. Liu Z.; Shi Y.; Yan Z.; Impact of anemia on the outcomes of chronic phase chronic myeloid leukemia in TKI era. Hematology 2020,25(1),181-185

2. Hochhaus A.; Baccarani M.; Silver R.T.; European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020,34(4),966-984

3. Samal P.; Chakrabarti P.; Nath U.K.; A prospective, randomized study to compare the combination of imatinib and cytarabine versus imatinib alone in newly diagnosed patients with chronic phase chronic myeloid leukemia. Indian J Cancer 2019,56(3),211-215

4. Phukan A.; Mandal P.K.; Dolai T.K.; Efficacy and safety profile of generic imatinib in patients with newly diagnosed chronic myeloid leukemia-chronic phase: Sharing experience of a hemato-oncology center from eastern India. Ann Hematol 2021,100(1),85-96

5. Okamoto S.; Ureshino H.; Kawaguchi A.; Miyazono M.; Ikeda Y.; Kimura S.; Assessment of estimated glomerular filtration rate in patients with chronic myeloid leukemia following discontinuation of tyrosine kinase inhibitors. Int J Hematol 2020,112(1),41-45